At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing antibody visugromab + nivolumab produced encouraging response with no new safety signals @AndreaNecchi dlvr.it/TW32cC
999 浏览 · 4 赞 · 2 转发 · 1 回复
Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.org- Yusuf Sadek@yusufksadek
@NatureMedicine @AndreaNecchi CPS didn't separate responders here, but baseline CD8+ and CD8+Ki-67+ T cell density on mIF did (p = 0.008 and 0.003 in the visugromab arm). Would a plain H&E TIL score on the baseline TURBT slides pick up the same signal, since every center already has those
来源：Nature Medicine · x.com